Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 20/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.64 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14150188 | 1.00 | EPHX2 (1.00) | EPHX2CYP2C19EPHX1 | |
| SCHEMBL18465002 | 1.00 | EPHX2 (1.00) | EPHX2CYP2C19EPHX1 | |
| SCHEMBL653866 | 1.00 | EPHX2 (1.00) | EPHX2CYP2C19EPHX1 | |
| SCHEMBL12931839 | 0.89 | EPHX2 (0.80) | EPHX2 | |
| SCHEMBL15272724 | 0.88 | EPHX2 (1.00) | EPHX2 | |
| SCHEMBL15272793 | 0.88 | EPHX2 (1.00) | EPHX2 | |
| SCHEMBL1062800 | 0.87 | EPHX2 (1.00) | EPHX2 | |
| SCHEMBL3195594 | 0.87 | EPHX2 (1.00) | EPHX2 | |
| SCHEMBL1065991 | 0.87 | EPHX2 (1.00) | EPHX2 | |
| SCHEMBL3183514 | 0.87 | EPHX2 (1.00) | EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260130877-A1 | TREATMENT OF NEURODEVELOPMENTAL DISORDERS | THE REGENTS OF THE UNIV OF CALIFORNIA (US) | 2026-05-14 | — | — | US | claimed |
| US-20230301949-A1 | TREATMENT OF NEURODEVELOPMENTAL DISORDERS | CHIBA UNIVERSITY (JP) | 2023-09-28 | — | — | US | claimed |
| US-11723929-B2 | Methods of improving cell-based therapy | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-08-15 | — | — | US | claimed |
| US-11690837-B2 | Methods of improving cell-based therapy | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-07-04 | — | — | US | claimed |
| US-11564914-B2 | Methods of treating bone loss | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-01-31 | — | — | US | claimed |
| US-20220202744-A1 | METHODS OF TREATING MENTAL DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2022-06-30 | — | — | US | claimed |
| US-20210378995-A1 | METHODS AND TOPICAL PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF SKIN MICROVASCULAR DYSFUNCTION | UNIVERSITE DE ROUEN NORMANDIE (FR) | 2021-12-09 | — | — | US | claimed |
| EP-3863639-A1 | METHODS AND TOPICAL PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF SKIN MICROVASCULAR DYSFUNCTION | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2021-08-18 | — | — | EP | claimed |
| US-20210145891-A1 | METHODS OF IMPROVING CELL-BASED THERAPY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2021-05-20 | — | — | US | claimed |
| US-20200306232-A1 | METHODS OF TREATING BONE LOSS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-10-01 | — | — | US | claimed |
| US-20190125696-A1 | METHODS OF TREATING MENTAL DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-05-02 | — | — | US | claimed |
| WO-2018231702-A1 | METHODS OF IMPROVING CELL-BASED THERAPY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-12-20 | — | — | WO | claimed |
| US-20180200244-A1 | METHODS OF IMPROVING CELL-BASED THERAPY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-07-19 | — | — | US | claimed |
| US-20180185309-A1 | METHODS AND COMPOSITIONS FOR TREATING NEPHROPATHY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-07-05 | — | — | US | claimed |
| US-7662910-B2 | Inhibitors for the soluble epoxide hydrolase | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-02-16 | — | — | US | claimed |
| US-20260130877-A1 | TREATMENT OF NEURODEVELOPMENTAL DISORDERS | THE REGENTS OF THE UNIV OF CALIFORNIA (US) | 2026-05-14 | — | — | US | disclosed |
| US-12485107-B2 | Methods for the prevention or treatment of cytokine storm | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2025-12-02 | — | — | US | disclosed |
| US-7662910-B2 | Inhibitors for the soluble epoxide hydrolase | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-02-16 | — | — | US | disclosed |
| WO-2009062073-A1 | ALLEVIATING NEUROPATHIC PAIN WITH EETS AND SEH INHIBITORS | REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-05-14 | — | — | WO | disclosed |
| WO-2009020960-A1 | PREPARATION OF NOVEL 1,3-SUBSTITUTED UREAS AS INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200306232-A1 | METHODS OF TREATING BONE LOSS | EPHX1, NCEH1, SOST | EPHX2 4/4885CYP2C19 3862/4885EPHX1 1/4885 |
| US-20230301949-A1 | TREATMENT OF NEURODEVELOPMENTAL DISORDERS | FABP7, ADH1B, ELOVL1 | EPHX2 51/4885CYP2C19 3526/4885EPHX1 25/4885 |
| US-11723929-B2 | Methods of improving cell-based therapy | EPHX1, EPHX2, NCEH1 | EPHX2 2/4885CYP2C19 2261/4885EPHX1 1/4885 |
| US-20180200244-A1 | METHODS OF IMPROVING CELL-BASED THERAPY | ELOVL1, ELOVL3, IL2 | EPHX2 127/4885CYP2C19 3558/4885EPHX1 116/4885 |
| US-20220202744-A1 | METHODS OF TREATING MENTAL DISORDERS | FAAH, EPHX1, FAAH2 | EPHX2 4/4885CYP2C19 799/4885EPHX1 2/4885 |
| US-20260130877-A1 | TREATMENT OF NEURODEVELOPMENTAL DISORDERS | EED, ICOS, FABP7 | EPHX2 10/4885CYP2C19 676/4885EPHX1 8/4885 |
| US-11690837-B2 | Methods of improving cell-based therapy | ELOVL1, ELOVL3, IL2 | EPHX2 127/4885CYP2C19 3558/4885EPHX1 116/4885 |
| US-11564914-B2 | Methods of treating bone loss | EPHX1, NCEH1, SOST | EPHX2 4/4885CYP2C19 3862/4885EPHX1 1/4885 |
| US-12485107-B2 | Methods for the prevention or treatment of cytokine storm | TNF, PTGES2, IL2 | EPHX2 13/4885CYP2C19 2444/4885EPHX1 5/4885 |
| US-20180185309-A1 | METHODS AND COMPOSITIONS FOR TREATING NEPHROPATHY | GLS, REN, SLC5A2 | EPHX2 3353/4885CYP2C19 4879/4885EPHX1 2595/4885 |
| US-20210145891-A1 | METHODS OF IMPROVING CELL-BASED THERAPY | EPHX1, EPHX2, NCEH1 | EPHX2 2/4885CYP2C19 2261/4885EPHX1 1/4885 |
| US-20190125696-A1 | METHODS OF TREATING MENTAL DISORDERS | FAAH, EPHX1, FAAH2 | EPHX2 4/4885CYP2C19 799/4885EPHX1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.